{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T21:29:10Z","timestamp":1795210150868,"version":"4.10.3"},"reference-count":74,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.dld.2020.09.022","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T08:14:42Z","timestamp":1602317682000},"page":"403-408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Medical therapy versus surgery in moderate-to-severe ulcerative colitis"],"prefix":"10.1016","volume":"53","author":[{"given":"Gionata","family":"Fiorino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Giacobazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2020.09.022_bib0001","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMra1102942","article-title":"Ulcerative colitis","volume":"365","author":"Danese","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2020.09.022_bib0002","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European evidence-based consensus on diagnosis and management of Ulcerative Colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2020.09.022_bib0003","doi-asserted-by":"crossref","first-page":"9458","DOI":"10.3748\/wjg.v20.i28.9458","article-title":"Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis","volume":"20","author":"da Silva","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2020.09.022_bib0004","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med."},{"key":"10.1016\/j.dld.2020.09.022_bib0005","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The First European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease","volume":"10","author":"Harbord","year":"2015","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.dld.2020.09.022_bib0006","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ecco-jcc\/jjv141","article-title":"European Evidence-based Consensus: inflammatory Bowel Disease and Malignancies","volume":"9","author":"Annese","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2020.09.022_bib0007","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2020.09.022_bib0008","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1111\/bcp.14051","article-title":"Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: a systematic review and network meta-analysis","volume":"85","author":"Bonovas","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dld.2020.09.022_bib0009","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn's disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2020.09.022_bib0010","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/apt.14030","article-title":"Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials","volume":"45","author":"Cholapranee","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2020.09.022_bib0011","doi-asserted-by":"crossref","first-page":"704","DOI":"10.7326\/M13-2403","article-title":"Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis","volume":"160","author":"Danese","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dld.2020.09.022_bib0012","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus Adalimumab for moderate-to-severe Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2020.09.022_bib0013","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1053\/j.gastro.2015.02.058","article-title":"In the presence of conceptual heterogeneity, results of network meta-analysis comparing therapies in crohn's disease need to be interpreted with caution","volume":"148","author":"Bonovas","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2020.09.022_bib0014","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/00365520802600961","article-title":"Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)","volume":"44","author":"Solberg","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.dld.2020.09.022_bib0015","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2020.09.022_bib0016","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.crohns.2008.03.004","article-title":"Long-term outcome after infliximab for refractory ulcerative colitis","volume":"2","author":"Ferrante","year":"2008","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2020.09.022_bib0017","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/14712598.2020.1701652","article-title":"Histological healing: should it be considered as a new outcome for ulcerative colitis?","volume":"20","author":"Dal Buono","year":"2020","journal-title":"Expert Opin Biol Ther."},{"key":"10.1016\/j.dld.2020.09.022_bib0018","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2020.09.022_bib0019","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/apt.15005","article-title":"Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life","volume":"48","author":"Paschos","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2020.09.022_bib0020","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2020.09.022_bib0021","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/jgh.12517","article-title":"Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis","volume":"29","author":"Hayes","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2020.09.022_bib0022","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.dld.2018.10.013","article-title":"Outcome in ulcerative colitis after switch from adalimumab\/golimumab to infliximab: a multicenter retrospective study","volume":"51","author":"Viola","year":"2019","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2020.09.022_bib0023","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2020.09.022_bib0024","first-page":"317","article-title":"Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results","volume":"9","year":"2013","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.dld.2020.09.022_bib0025","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/ajg.2014.242","article-title":"Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ULTRA 1, 2, and 3","volume":"109","author":"Colombel","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2020.09.022_bib0026","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.dld.2020.09.022_bib0027","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2020.09.022_bib0028","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2020.09.022_bib0029","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1586\/eci.10.40","article-title":"Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease","volume":"6","author":"Fiorino","year":"2010","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.dld.2020.09.022_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2016.08.044","article-title":"Efficacy of Vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists","volume":"15","author":"Feagan","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2020.09.022_bib0031","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/ibd\/izz057","article-title":"Comparative efficacy of Vedolizumab and Adalimumab in ulcerative colitis patients previously treated with Infliximab","volume":"25","author":"Favale","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2020.09.022_bib0032","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.dld.2020.09.022_bib0033","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for Ulcerative Colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2020.09.022_bib0034","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.suc.2015.07.003","article-title":"Indications and options for surgery in Ulcerative Colitis","volume":"95","author":"Bohl","year":"2015","journal-title":"Surg Clin North Am"},{"key":"10.1016\/j.dld.2020.09.022_bib0035","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1053\/j.gastro.2009.08.024","article-title":"Is keeping the colon the ultimate marker of success in Ulcerative Colitis?","volume":"137","author":"Nguyen","year":"2009","journal-title":"Gastroenterology."},{"key":"10.1016\/j.dld.2020.09.022_bib0036","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/apt.12289","article-title":"Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience","volume":"37","author":"Laharie","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2020.09.022_bib0037","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/imj.12397","article-title":"Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy","volume":"44","author":"Subramaniam","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.dld.2020.09.022_bib0038","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000493121","article-title":"Assessment of long-term efficacy and safety of Adalimumab in patients with Ulcerative Colitis: results from a 6-year real-world clinical practice","volume":"37","author":"Sugimoto","year":"2019","journal-title":"Dig Dis"},{"key":"10.1016\/j.dld.2020.09.022_bib0039","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/MIB.0000000000001144","article-title":"Clinical outcomes of Golimumab as first, second or third anti-TNF Agent in patients with moderate-to-severe Ulcerative Colitis","volume":"23","author":"Taxonera","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2020.09.022_bib0040","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","article-title":"Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study","volume":"128","author":"Jarnerot","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2020.09.022_bib0041","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.2174\/1389450120666190426165325","article-title":"Are surgical rates decreasing in the biological era In IBD?","volume":"20","author":"Candido","year":"2019","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.dld.2020.09.022_bib0042","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s11605-019-04474-9","article-title":"Decreasing Colectomy rates in ulcerative colitis in the past decade: improved disease control?","volume":"24","author":"Ghoz","year":"2020","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.dld.2020.09.022_bib0043","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/00365521.2019.1620326","article-title":"Impact of anti-TNF-alpha therapy on colectomy rate and indications for colectomy in ulcerative colitis: comparison of two patient cohorts from 2005 to 2007 and from 2014 to 2016","volume":"54","author":"Kolehmainen","year":"2019","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.dld.2020.09.022_bib0044","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40271-013-0031-2","article-title":"Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data","volume":"6","author":"Bewtra","year":"2013","journal-title":"Patient"},{"key":"10.1016\/j.dld.2020.09.022_bib0045","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s10620-018-4922-x","article-title":"Mortality is rare following elective and non-elective surgery for ulcerative colitis, but mild postoperative complications are common","volume":"63","author":"Feuerstein","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2020.09.022_bib0046","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/apt.13763","article-title":"Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis","volume":"44","author":"Peyrin-Biroulet","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2020.09.022_bib0047","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1111\/j.1572-0241.2008.02054.x","article-title":"Does it matter where you are hospitalized for inflammatory bowel disease? A nationwide analysis of hospital volume","volume":"103","author":"Ananthakrishnan","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2020.09.022_bib0048","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1080\/00365521.2017.1337218","article-title":"Predictors of quality-of-life after ileal pouch-anal anastomosis in patients with ulcerative colitis","volume":"52","author":"Abolfotouh","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.dld.2020.09.022_bib0049","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.3748\/wjg.v16.i40.5024","article-title":"Health related quality of life in inflammatory bowel disease: the impact of surgical therapy","volume":"16","author":"Umanskiy","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2020.09.022_bib0050","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/DCR.0b013e318251e004","article-title":"Timing of restorative proctocolectomy in patients with medically refractory ulcerative colitis: the patient's point of view","volume":"55","author":"Neumann","year":"2012","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.dld.2020.09.022_bib0051","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/apt.14449","article-title":"Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis","volume":"47","author":"Bonovas","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2020.09.022_bib0052","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/DCR.0000000000001276","article-title":"Outcomes for Ulcerative Colitis with delayed emergency colectomy are worse when controlling for preoperative risk factors","volume":"62","author":"Leeds","year":"2019","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.dld.2020.09.022_bib0053","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.surg.2012.08.002","article-title":"Prolonged preoperative hospitalization correlates with worse outcomes after colectomy for acute fulminant ulcerative colitis","volume":"153","author":"Coakley","year":"2013","journal-title":"Surgery"},{"key":"10.1016\/j.dld.2020.09.022_bib0054","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/ecco-jcc\/jjw156","article-title":"The IBD disability index should become a major secondary endpoint in clinical practice and in clinical trials","volume":"10","author":"Peyrin-Biroulet","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2020.09.022_bib0055","first-page":"1237","article-title":"[Disability in inflammatory bowel disease: an underestimated problem]","volume":"64","author":"Vuitton","year":"2014","journal-title":"Rev Prat"},{"key":"10.1016\/j.dld.2020.09.022_bib0056","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/apt.12187","article-title":"Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease","volume":"37","author":"Allen","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2020.09.022_bib0057","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/gutjnl-2011-300049","article-title":"Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health","volume":"61","author":"Peyrin-Biroulet","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.dld.2020.09.022_bib0058","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1159\/000320403","article-title":"What is the patient's perspective: how important are patient-reported outcomes, quality of life and disability?","volume":"28","author":"Peyrin-Biroulet","year":"2010","journal-title":"Dig Dis"},{"key":"10.1016\/j.dld.2020.09.022_bib0059","first-page":"11","article-title":"ical Conundrum","volume":"22","year":"2020","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.dld.2020.09.022_bib0060","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bpg.2018.05.017","article-title":"Surgery in ulcerative colitis: when? How?","volume":"32-33","author":"Gallo","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.dld.2020.09.022_bib0061","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/SLA.0b013e31827d99a2","article-title":"Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients","volume":"257","author":"Fazio","year":"2013","journal-title":"Ann Surg"},{"key":"10.1016\/j.dld.2020.09.022_bib0062","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/ecco-jcc\/jjz187","article-title":"ECCO guidelines on therapeutics in Crohn's disease: surgical treatment","volume":"14","author":"Adamina","year":"2019","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.dld.2020.09.022_bib0063","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","article-title":"Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis","volume":"14","author":"Bonovas","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2020.09.022_bib0064","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cgh.2010.09.026","article-title":"Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease","volume":"9","author":"Cottone","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2020.09.022_bib0065","unstructured":"European Medicine Agency. EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots. Press release 15\/11\/2019. Available at:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/xeljanz."},{"key":"10.1016\/j.dld.2020.09.022_bib0066","unstructured":"Food and Drug Administration. FDA approves boxed warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR). Posted 26\/7\/2019. Available at:. 2019, https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/xeljanz-xeljanz-xr-tofacitinib-drug-safety-communication-due-increased-risk-blood-clots-and-death."},{"key":"10.1016\/j.dld.2020.09.022_bib0067","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1136\/gutjnl-2013-305763","article-title":"Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer","volume":"63","author":"Beaugerie","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.dld.2020.09.022_bib0068","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","article-title":"Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF\u03b1 therapy: results from the COIN study","volume":"63","author":"van der Valk","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.dld.2020.09.022_bib0069","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/ecco-jcc\/jjv134","article-title":"Comparison of costs and quality of life in Ulcerative Colitis patients with an Ileal Pouch-Anal Anastomosis, Ileostomy and Anti-TNF\u03b1 Therapy","volume":"9","author":"van der Valk","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2020.09.022_bib0070","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.surg.2019.04.045","article-title":"Does laparoscopic ileal pouch-anal anastomosis reduce infertility compared with open approach?","volume":"166","author":"Gorgun","year":"2019","journal-title":"Surgery"},{"key":"10.1016\/j.dld.2020.09.022_bib0071","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/SLA.0b013e3182813741","article-title":"A total laparoscopic approach reduces the infertility rate after ileal pouch-anal anastomosis: a 2-center study","volume":"258","author":"Beyer-Berjot","year":"2013","journal-title":"Ann Surg"},{"key":"10.1016\/j.dld.2020.09.022_bib0072","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1097\/SLA.0b013e318250caa9","article-title":"Significantly increased pregnancy rates after laparoscopic restorative proctocolectomy: a cross-sectional study","volume":"256","author":"Bartels","year":"2012","journal-title":"Ann Surg"},{"key":"10.1016\/j.dld.2020.09.022_bib0073","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/ecco-jcc\/jjy140","article-title":"'Quality of Care' standards in inflammatory bowel disease: a Systematic Review","volume":"13","author":"Fiorino","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2020.09.022_bib0074","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/j.gastro.2008.01.004","article-title":"Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis","volume":"134","author":"Kaplan","year":"2008","journal-title":"Gastroenterology"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865820305028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865820305028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:14:57Z","timestamp":1761624897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865820305028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1590865820305028"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2020.09.022","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical therapy versus surgery in moderate-to-severe ulcerative colitis","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2020.09.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}